0001437749-11-009576.txt : 20111216 0001437749-11-009576.hdr.sgml : 20111216 20111216163156 ACCESSION NUMBER: 0001437749-11-009576 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111214 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20111216 DATE AS OF CHANGE: 20111216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 111266726 BUSINESS ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 hxbm_8k-121411.htm CURRENT REPORT hxbm_8k-121411.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
 
FORM 8-K
_______________
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 14, 2011

_______________
 
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
 
_______________
 
DELAWARE
033-20897-D
91-2099117
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(IRS Employer
Identification No.)
 
22118 20th Avenue S.E., Suite 204
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)

_______________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 1.01
Entry into a Material Definitive Agreement.
 
On December 14, 2011, the Company entered into a Third Amendment to First Amended and Restated License Agreement (the “Third Amendment”) with Grant Industries, Inc., which amends the First Amended and Restated License Agreement between the parties dated September 12, 2007 as amended effective as of December 10, 2008 and May 6, 2010 (the “Agreement”). The Third Amendment (i) removes one of the Company’s proprietary peptides from the scope of the license granted pursuant to the Agreement, (ii) requires that the peptides subject to such license be purchased from the Company, (iii) extends the term of the Agreement until December 31, 2014 and (iv) establishes minimum royalty obligations for 2012, 2013 and 2014.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
HELIX BIOMEDIX, INC.
       
Dated: December 16, 2011
  
By:
/s/ R. Stephen Beatty
     
R. Stephen Beatty
     
President and Chief Executive Officer